GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Cyclically Adjusted Book per Share

Paratek Pharmaceuticals (FRA:N4CN) Cyclically Adjusted Book per Share : €5.59 (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Paratek Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2023 was €-3.245. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.59 for the trailing ten years ended in Jun. 2023.

During the past 12 months, Paratek Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -51.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -28.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -23.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Paratek Pharmaceuticals was -10.40% per year. The lowest was -28.90% per year. And the median was -19.30% per year.

As of today (2024-06-11), Paratek Pharmaceuticals's current stock price is €2.024. Paratek Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €5.59. Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.36.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Paratek Pharmaceuticals was 0.65. The lowest was 0.11. And the median was 0.28.


Paratek Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Paratek Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Cyclically Adjusted Book per Share Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.02 22.74 17.43 13.58 8.18

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.43 9.76 8.18 6.86 5.59

Competitive Comparison of Paratek Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Paratek Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Paratek Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book= Book Value per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-3.245/128.7287*128.7287
=-3.245

Current CPI (Jun. 2023) = 128.7287.

Paratek Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201309 36.424 98.790 47.462
201312 33.354 98.326 43.667
201403 32.052 99.695 41.387
201406 19.299 100.560 24.705
201409 16.627 100.428 21.313
201412 5.356 99.070 6.959
201503 5.417 99.621 7.000
201506 7.153 100.684 9.145
201509 6.083 100.392 7.800
201512 5.278 99.792 6.808
201603 3.719 100.470 4.765
201606 4.187 101.688 5.300
201609 3.366 101.861 4.254
201612 2.906 101.863 3.672
201703 3.080 102.862 3.855
201706 3.656 103.349 4.554
201709 3.004 104.136 3.713
201712 2.494 104.011 3.087
201803 2.857 105.290 3.493
201806 2.307 106.317 2.793
201809 1.554 106.507 1.878
201812 1.296 105.998 1.574
201903 0.438 107.251 0.526
201906 -0.372 108.070 -0.443
201909 -1.121 108.329 -1.332
201912 -0.896 108.420 -1.064
202003 -1.180 108.902 -1.395
202006 -1.244 108.767 -1.472
202009 -1.486 109.815 -1.742
202012 -1.807 109.897 -2.117
202103 -2.131 111.754 -2.455
202106 -1.717 114.631 -1.928
202109 -1.784 115.734 -1.984
202112 -2.187 117.630 -2.393
202203 -2.403 121.301 -2.550
202206 -2.579 125.017 -2.656
202209 -3.027 125.227 -3.112
202212 -2.850 125.222 -2.930
202303 -3.082 127.348 -3.115
202306 -3.245 128.729 -3.245

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Paratek Pharmaceuticals  (FRA:N4CN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.024/5.59
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Paratek Pharmaceuticals was 0.65. The lowest was 0.11. And the median was 0.28.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Paratek Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines